Effect of linagliptin versus placebo on cardiovascular and kidney outcomes in nephrotic-range proteinuria and type 2 diabetes: the CARMELINA randomized controlled trial

BACKGROUND: Nephrotic-range proteinuria (NRP) is associated with rapid kidney function loss and increased cardiovascular (CV) disease risk. We assessed the effects of linagliptin (LINA) on CV and kidney outcomes in people with Type 2 diabetes (T2D) with or without NRP. METHODS: Cardiovascular and re...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Clin Kidney J
Asıl Yazarlar: Wanner, Christoph, Cooper, Mark E, Johansen, Odd Erik, Toto, Robert, Rosenstock, Julio, McGuire, Darren K, Kahn, Steven E, Pfarr, Egon, Schnaidt, Sven, von Eynatten, Maximilian, George, Jyothis T, Gollop, Nicholas D, Marx, Nikolaus, Alexander, John H, Zinman, Bernard, Perkovic, Vlado
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Oxford University Press 2021
Konular:
Original Articles
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC7857804/
https://ncbi.nlm.nih.gov/pubmed/33564423
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/ckj/sfaa225
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller